argenx meets primary endpoint in Phase II celiac disease study

argenx meets primary endpoint in Phase II celiac disease study: the analysis positions ARGX, JNJ and NVS to benefit and TAK, GIS and HALO under pressure; confidence high.

Analyzed 2026-10-09 — point-in-time, never revised. Outcomes are scored against SPY and published either way.

Ranked exposures

▲ ARGX argenx — impact +90 · confidence high · horizon immediate · 1st order
Argenx's validated celiac asset de-risks entry into a large untreated market, raising future revenue expectations beyond Vyvgart.
Chain: Phase 2 celiac trial meets primary endpoint → FB102 de-risks a new autoimmune indication → celiac population is large and pharmacologically untreated → pipeline value beyond Vyvgart rerates higher
What would break the call: A Phase 3 readout showing no histologic benefit removes the celiac revenue option.
▼ TAK Takeda — impact -40 · confidence medium · horizon quarters · 2nd order
Argenx's advancing celiac therapy intensifies competition, reducing Takeda's expected revenue from its own celiac program.
Chain: argenx validates a celiac drug mechanism → competitive pressure lands on Takeda celiac assets → Takeda faces share loss in a nascent market → expected celiac franchise revenue is discounted
What would break the call: Takeda posts superior Phase 3 celiac efficacy data and restores its first mover position.
▼ GIS General Mills — impact -40 · confidence low · horizon quarters · 3rd order
General Mills gluten free product revenue falls as argenx celiac treatment reduces consumer need for special diets.
Chain: effective celiac drug advances toward registration → diagnosed patients expect to widen their diets → gluten free specialty food volume growth slows → General Mills gluten free lines decelerate
What would break the call: Gluten free demand stays driven by non celiac shoppers and category volume growth holds.
▼ HALO Halozyme — impact -35 · confidence low · horizon quarters · 2nd order
Halozyme loses royalty bearing volume because the subcutaneous Sjogren's trial using its delivery technology was stopped for futility.
Chain: subcutaneous Sjogren's Phase 3 halted for futility → a future Vyvgart Hytrulo indication disappears → ENHANZE royalty bearing volume forecast falls → Halozyme long run royalty revenue trimmed
What would break the call: Other subcutaneous efgartigimod indications launch and more than replace the lost Sjogren's volume.
▼ IMVT Immunovant — impact -32 · confidence low · horizon immediate · 2nd order
Immunovant faces a harsher read across for FcRn blockade in antibody driven disease after the Sjogren's futility call.
Chain: FcRn blockade fails a Sjogren's futility analysis → investors question FcRn breadth beyond IgG driven disease → batoclimab and IMVT-1402 indication expectations reset → probability weighted pipeline value falls
What would break the call: Immunovant reports positive IMVT-1402 data in a new indication and rebuts the class read across.
▲ JNJ Johnson & Johnson — impact +30 · confidence low · horizon quarters · 2nd order
Johnson & Johnson faces one fewer rival in Sjogren's disease after the competing FcRn Phase 3 was halted.
Chain: competing FcRn Sjogren's Phase 3 stops early → one fewer entrant in Sjogren's disease → nipocalimab faces a thinner competitive field → expected launch share and price improve
What would break the call: Nipocalimab misses its own Sjogren's endpoint and shows the failure was mechanism wide.
▲ NVS Novartis — impact +26 · confidence low · horizon quarters · 2nd order
Novartis advances ianalumab in Sjogren's disease against a thinner competitive field once the rival Phase 3 ends.
Chain: rival FcRn Sjogren's program discontinued → fewer competitors for ianalumab at launch → Novartis captures more Sjogren's patient share → immunology revenue outlook improves modestly
What would break the call: Ianalumab Phase 3 data disappoint and make the competitive clearing irrelevant.
▲ IQV IQVIA — impact +25 · confidence low · horizon weeks · 3rd order
IQVIA clinical research services demand increases when argenx celiac success spurs more industry trial activity.
Chain: celiac mechanism validated in Phase 2 → sponsors fund registrational celiac programs → outsourced clinical trial awards increase → IQVIA research solutions backlog grows
What would break the call: Biopharma research budget cuts offset new celiac awards and bookings growth stalls.
▲ SNY Sanofi — impact +25 · confidence low · horizon quarters · 2nd order
Sanofi holds an anti-IL-15 celiac antibody whose pathway just gained human proof, raising the odds its own trial succeeds.
Chain: FB102 blocks interleukin 15 signaling successfully → the IL-15 pathway gains human proof in celiac → Sanofi anti-IL-15 antibody success odds rise → celiac pipeline value inside Sanofi increases
What would break the call: Sanofi's own celiac readout misses endpoints and shows the two mechanisms behave differently.
▼ ROIV Roivant — impact -24 · confidence low · horizon immediate · 3rd order
Roivant carries the same FcRn exposure through its majority stake, so investor appetite for broad autoimmune expansion cools.
Chain: FcRn class read across weakens after futility → Immunovant equity value declines → Roivant majority stake marks lower → sum of parts valuation compresses
What would break the call: Immunovant delivers clean IMVT-1402 efficacy data and the stake value recovers.
▲ BMY Bristol Myers — impact +20 · confidence low · horizon quarters · 3rd order
Bristol Myers immunology drug revenue rises when argenx celiac success drives greater patient diagnoses and prescriptions.
Chain: celiac treatment prospects raise disease awareness → more autoimmune patients enter specialist care → immunology prescribing broadens across adjacent indications → Bristol Myers immunology revenue benefits modestly
What would break the call: Celiac testing growth stays inside gastroenterology with no spillover into immunology prescriptions.
▼ ZLAB Zai Lab — impact -18 · confidence low · horizon quarters · 2nd order
Zai Lab licenses efgartigimod for China and loses a future indication as the Sjogren's program ends.
Chain: efgartigimod Sjogren's Phase 3 stopped for futility → a licensed China indication is removed → Zai Lab long run efgartigimod sales shrink → China autoimmune revenue outlook trimmed
What would break the call: Zai Lab adds other efgartigimod indications in China and replaces the lost sales pool.
▲ AMGN Amgen — impact +14 · confidence low · horizon quarters · 3rd order
Amgen originated the anti-IL-15 antibody licensed for celiac disease and keeps economics tied to that partnered program advancing.
Chain: IL-15 pathway validated in celiac disease → the partnered anti-IL-15 antibody gains credibility → Amgen retains milestone and royalty economics → small pipeline option value increases
What would break the call: Amgen's residual economics prove negligible and no measurable financial benefit appears.
▲ DGX Quest Diagnostics — impact +12 · confidence low · horizon quarters · 2nd order
Quest Diagnostics processes celiac serology panels, and a coming drug pushes physicians to test more symptomatic patients.
Chain: an approaching celiac therapy raises testing intent → physicians order more transglutaminase serology panels → Quest requisition volume increases → diagnostic information services revenue grows
What would break the call: Payers restrict celiac serology screening and cap the test volume increase.
▲ LH Labcorp — impact +12 · confidence low · horizon quarters · 2nd order
Labcorp sees similar celiac antibody testing volume growth as treatment prospects move undiagnosed patients into formal workups.
Chain: celiac drug prospects move undiagnosed patients into workups → antibody testing and biopsy referrals increase → Labcorp specialty test volume rises → diagnostics segment revenue growth improves
What would break the call: Celiac testing stays flat because guidelines do not change ahead of an approval.
▲ MEDP Medpace — impact +12 · confidence low · horizon quarters · 2nd order
Medpace books enrollment heavy biopsy based celiac studies as the sponsor funds a global Phase 3 program.
Chain: argenx funds a global celiac Phase 3 → biopsy heavy enrollment work is outsourced → Medpace wins immunology trial awards → backlog and service revenue grow
What would break the call: The sponsor assigns celiac Phase 3 work to a large global CRO instead.
▲ ICLR ICON — impact +10 · confidence low · horizon quarters · 2nd order
ICON competes for the same late stage immunology outsourcing dollars that a new celiac Phase 3 creates.
Chain: validated celiac mechanism triggers late stage programs → sponsors tender large immunology outsourcing contracts → ICON competes for those registrational awards → net new business and backlog improve
What would break the call: ICON loses the celiac awards to rivals and cancellations keep net bookings negative.
▲ TMO Thermo Fisher — impact +10 · confidence low · horizon quarters · 2nd order
Thermo Fisher sells celiac autoantibody assays and clinical trial services, both pulled along by wider diagnosis and registrational work.
Chain: celiac diagnosis and treatment activity broadens → autoantibody assay reagent demand increases → PPD wins clinical trial service work → specialty diagnostics and services revenue rise
What would break the call: Pharma services demand stays weak and offsets any diagnostics reagent volume gain.
▼ HAIN Hain Celestial — impact -8 · confidence low · horizon quarters · 3rd order
Hain Celestial depends on gluten-free grocery demand that erodes slowly once drug treatment lets diagnosed patients widen diets.
Chain: celiac drug lets diagnosed patients widen diets → gluten free grocery demand erodes slowly → Hain snack and baking volumes decline → organic net sales growth weakens further
What would break the call: Gluten free purchases remain lifestyle driven and Hain category volumes keep growing.
▲ QDEL QuidelOrtho — impact +8 · confidence low · horizon quarters · 2nd order
QuidelOrtho sells celiac autoantibody immunoassays to clinical labs and gains reagent volume as physicians test more symptomatic patients.
Chain: treatable celiac diagnosis raises testing incentive → labs run more serology panels → QuidelOrtho immunoassay reagent pull through rises → specialty diagnostics revenue grows modestly
What would break the call: Respiratory testing declines dominate results and mask any celiac reagent volume gain.
▲ BIO Bio-Rad Laboratories — impact +6 · confidence low · horizon quarters · 2nd order
Bio-Rad sells multiplex celiac antibody panels on BioPlex systems and benefits as diagnostic testing volumes expand.
Chain: celiac treatment prospect widens patient screening → multiplex autoimmune panel orders increase → Bio-Rad reagent consumption rises → clinical diagnostics segment revenue improves
What would break the call: Labs consolidate celiac testing onto competing platforms and Bio-Rad reagent volume stays flat.
▲ CRL Charles River Laboratories — impact +6 · confidence low · horizon quarters · 3rd order
Validated celiac biology pushes rivals to start preclinical programs that require Charles River safety assessment and model services.
Chain: celiac mechanism proof attracts new entrants → discovery and preclinical programs are funded → safety assessment study bookings rise → Charles River backlog improves
What would break the call: Biotech funding stays tight and preclinical bookings keep declining despite new celiac interest.
▲ WST West Pharmaceutical Services — impact +6 · confidence low · horizon quarters · 3rd order
West supplies elastomer and syringe components for subcutaneous antibody launches that expand as argenx scales new autoimmune indications.
Chain: new antibody indications reach registrational scale → subcutaneous and injectable volumes increase → demand rises for stoppers and delivery components → West high value product revenue grows
What would break the call: Customer destocking continues and West component orders fall despite rising end market volumes.
▼ UNFI United Natural Foods — impact -5 · confidence low · horizon quarters · 3rd order
United Natural Foods distributes gluten free specialty grocery whose case volume softens once drug treatment reduces strict diet adherence.
Chain: celiac therapy reduces dietary necessity → gluten free specialty demand growth slows → natural product case volumes soften → UNFI wholesale revenue growth weakens
What would break the call: Gluten free remains a lifestyle category and UNFI case volumes continue growing.

Sources

What happened

Horizon	Verdict	Top pick	Excess vs SPY
1 trading days	Mixed	ARGX	+0.2% vs SPY

Related scenarios

Stocks in this scenario

ARGX · TAK · GIS · HALO · IMVT · JNJ · NVS · IQV · SNY · ROIV · BMY · ZLAB · AMGN · DGX · LH · MEDP · ICLR · TMO · HAIN · QDEL · BIO · CRL · WST · UNFI

News events · All scenarios · Pricing · Track record · Methodology · Map your own scenario